Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics
Cationic polymers are promising antibacterial agents since they have a low propensity for bacteria to evolve resistance, but they usually have low biocompatibility due to their hydrophobic moieties. Herein, we report a new biodegradable and biocompatible chitosan-derived cationic antibacterial polym...
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2021
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/153841 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-153841 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-1538412023-02-28T17:08:37Z Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics Si, Zhangyong Hou, Zheng Vikhe, Yogesh Shankar Thappeta, Kishore Reddy Venkata Marimuthu, Kalisvar De, Partha Pratim Ng, Oon Tek Li, Peng Zhu, Yabin Pethe, Kevin Chan-Park, Mary B. School of Chemical and Biomedical Engineering Lee Kong Chian School of Medicine (LKCMedicine) School of Biological Sciences Centre for Antimicrobial Bioengineering Engineering::Chemical engineering::Polymers and polymer manufacture Antibacterial Chitosan Derivatives Cationic polymers are promising antibacterial agents since they have a low propensity for bacteria to evolve resistance, but they usually have low biocompatibility due to their hydrophobic moieties. Herein, we report a new biodegradable and biocompatible chitosan-derived cationic antibacterial polymer, 2,6-Diamino Chitosan (2,6-DAC). 2,6-DAC shows excellent broad-spectrum antimicrobial activity with minimum inhibitory concentrations (MICs) of 8-32 µg/mL against clinically relevant and multi-drug resistant (MDR) bacteria including Listeria monocytogenes, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Further, 2,6-DAC shows an excellent synergistic effect with various clinically relevant antibiotics proved by decreasing the MICs of the antibiotics against MDR A. baumannii and MRSA to <1 µg/mL. In vivo biocompatibility of 2,6-DAC is proved by a dosage of 100 mg/kg compound via the oral administration and 25 mg/kg compound via intraperitoneal injection to mice; 2,6-DAC does not cause any weight loss and any significant change in liver and kidney biomarkers nor the important blood electrolytes. The combinations of 2,6-DAC together with novobiocin and rifampicin show >2.4 log10 reduction of A. baumannii in murine intraperitoneal and lung infection models. The novel chitosan derivative, 2,6-DAC, can be utilized as biocompatible broad-spectrum cationic antimicrobial agent alone or in synergistic combination with various antibiotics. Agency for Science, Technology and Research (A*STAR) Ministry of Education (MOE) Ministry of Health (MOH) Nanyang Technological University Accepted version We thank the funding support from Singapore Ministry of Education Tier 3 grants (MOE2013-T3-1-002, MOE2018-T3-1-003), a Singapore Ministry of Health Industry Alignment Fund (NMRC/ MOHIAFCAT2/003/2014) and NTU. We also thank the ASTAR Wound Care Innovation for the Tropics IAF-PP (HBMS Domain) with grant number H17/01/a0/0M9, and ASTAR RIE2020 Advanced Manufacturing and Engineering (AME) IAP-PP Specialty Chemicals Programme (Grant No. A1786a0032). We also thank the Major Project of 2025 Sci&Tech Innovation of Ningbo (2018B10052) and NSF of China, 8147179. 2021-12-13T00:27:22Z 2021-12-13T00:27:22Z 2021 Journal Article Si, Z., Hou, Z., Vikhe, Y. S., Thappeta, K. R. V., Marimuthu, K., De, P. P., Ng, O. T., Li, P., Zhu, Y., Pethe, K. & Chan-Park, M. B. (2021). Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics. ACS Applied Materials & Interfaces, 13(2), 3237-3245. https://dx.doi.org/10.1021/acsami.0c20881 1944-8244 https://hdl.handle.net/10356/153841 10.1021/acsami.0c20881 2 13 3237 3245 en MOE2013-T3-1-002 MOE2018-T3-1-003 NMRC/MOHIAFCAT2/003/2014 H17/01/a0/ 0M9 A1786a0032 ACS Applied Materials & Interfaces This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Applied Materials & Interfaces, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acsami.0c20881. application/pdf application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Engineering::Chemical engineering::Polymers and polymer manufacture Antibacterial Chitosan Derivatives |
spellingShingle |
Engineering::Chemical engineering::Polymers and polymer manufacture Antibacterial Chitosan Derivatives Si, Zhangyong Hou, Zheng Vikhe, Yogesh Shankar Thappeta, Kishore Reddy Venkata Marimuthu, Kalisvar De, Partha Pratim Ng, Oon Tek Li, Peng Zhu, Yabin Pethe, Kevin Chan-Park, Mary B. Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics |
description |
Cationic polymers are promising antibacterial agents since they have a low propensity for bacteria to evolve resistance, but they usually have low biocompatibility due to their hydrophobic moieties. Herein, we report a new biodegradable and biocompatible chitosan-derived cationic antibacterial polymer, 2,6-Diamino Chitosan (2,6-DAC). 2,6-DAC shows excellent broad-spectrum antimicrobial activity with minimum inhibitory concentrations (MICs) of 8-32 µg/mL against clinically relevant and multi-drug resistant (MDR) bacteria including Listeria monocytogenes, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Further, 2,6-DAC shows an excellent synergistic effect with various clinically relevant antibiotics proved by decreasing the MICs of the antibiotics against MDR A. baumannii and MRSA to <1 µg/mL. In vivo biocompatibility of 2,6-DAC is proved by a dosage of 100 mg/kg compound via the oral administration and 25 mg/kg compound via intraperitoneal injection to mice; 2,6-DAC does not cause any weight loss and any significant change in liver and kidney biomarkers nor the important blood electrolytes. The combinations of 2,6-DAC together with novobiocin and rifampicin show >2.4 log10 reduction of A. baumannii in murine intraperitoneal and lung infection models. The novel chitosan derivative, 2,6-DAC, can be utilized as biocompatible broad-spectrum cationic antimicrobial agent alone or in synergistic combination with various antibiotics. |
author2 |
School of Chemical and Biomedical Engineering |
author_facet |
School of Chemical and Biomedical Engineering Si, Zhangyong Hou, Zheng Vikhe, Yogesh Shankar Thappeta, Kishore Reddy Venkata Marimuthu, Kalisvar De, Partha Pratim Ng, Oon Tek Li, Peng Zhu, Yabin Pethe, Kevin Chan-Park, Mary B. |
format |
Article |
author |
Si, Zhangyong Hou, Zheng Vikhe, Yogesh Shankar Thappeta, Kishore Reddy Venkata Marimuthu, Kalisvar De, Partha Pratim Ng, Oon Tek Li, Peng Zhu, Yabin Pethe, Kevin Chan-Park, Mary B. |
author_sort |
Si, Zhangyong |
title |
Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics |
title_short |
Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics |
title_full |
Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics |
title_fullStr |
Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics |
title_full_unstemmed |
Antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics |
title_sort |
antimicrobial effect of a novel chitosan derivative and its synergistic effect with antibiotics |
publishDate |
2021 |
url |
https://hdl.handle.net/10356/153841 |
_version_ |
1759854740753088512 |